Hims & Hers Health, Inc. HIMS
Email when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
The news check keeps the assessment current.
General analysis — not personal advice.
Hold existing position and monitor margin development as well as FTC outcome.
Strong revenue growth but clear margin pressure and new regulatory risk support a cautious stance.
Sentiment is neutral to mildly negative with heightened concern over legal penalties and brand damage.
HOLD is the call. Neutral is the market mood. High risk means a lot can go wrong.
Latest change
- 11 Nov 2026 — Report showed strong revenue growth but declining margins plus an FTC lawsuit that drove the share price drop.
The full analysis is open. Follow the company free for the full change history — and email next time the picture changes.
Show all changes (4) — follow the company freeAbout the company
Hims & Hers is a digital health platform connecting consumers with licensed providers via telehealth. The company offers subscription-based treatments for weight loss (GLP-1), hair loss, sexual health and mental health. Operations are expanding internationally through acquisitions with positive operating cash flow.
Bull case
Strong subscriber growth and international expansion via Eucalyptus provide continued top-line momentum.
Bear case
Shift to branded drugs and regulatory risks pressure margins and increase uncertainty.
Why this signal
Strong revenue growth but clear margin pressure and new regulatory risk support a cautious stance.
Recent news
Q3 results showed strong revenue growth but declining margins and a net loss. FTC together with Utah and California sued the company for unauthorized sharing of health data and misleading billing practices. The stock fell 16.6 % to 19.13 USD on very high volume on November 10.